ESTRO 36 Abstract Book

S708 ESTRO 36 _______________________________________________________________________________________________

RADIATION ONCOLOGY, MADRID, Spain 10 Consorcio Hospitalario Provincial de Castellón, RADIATION ONCOLOGY, CASTELLON, Spain 11 Fundación Hospital Provincial, BIOSTATISTICS, CASTELLON, Spain Purpose or Objective SBRT-SG 05 (ClinicalTrials.gov NCT02192788 ) is a collaborative (SBRT-SG, GICOR and SEOR) phase II trial testing SBRT and hormonotherapy in oligometastatic prostate cancer patients. The aim of this study is to determine response, and biochemical control rates, progression free survival, chemotherapy free survival and impact of treatment on quality of life. We describe here the protocol and first results. This type of studies are currently on the rise worldwide representing interest for Patients with histologically confirmed prostate cancer (hormone-sensitive or castration-resistant) in an oligorrecurrent stage after primary treatment for their disease were assigned to receive SBRT (Vertebral Metastases: 1x16-18Gy or 3x8-9Gy. Lymph node Metastases: 3x10-11 Gy or 6x7,5Gy. Non-spinal bone metastases: 1x16Gy or 3x10Gy). Medical treatment could include LHRH analogues or antiandrogens. The following Inclusion Criteria were established: Time to biochemical recurrence more than 1 year; PSA doubling time> 2 months; Less than 5 bone or lymph node metastases (including spinal) by Choline PET-CT or / and WB-DWI-MRI. To ensure homogeneity in the sample, all patients should have hormone therapy according to current recommendations planning its withdrawal within two years after treatment if biochemical control has been achieved. The percentage of castration resistance patients will be at most 30% and at least 10%of the sample. Concomitant treatment with chemotherapy, abiraterone or enzalutamide is not allowed. Results At present, 38 patients have been recruited in 10 centers, with 47 locations of oligometastases treated. 3 patients have been evaluated at 18 months, 6 have been evaluated at year, 4 at 9 months, 3 at 6 months, 7 at 3 months, 9 at 1 month, 2 just have been recieved SBRT now and 2 are pending to the initial studies. 2 patients were lost in follow-up. In all there is local and biochemical control. No patient had symptoms related to local progression. 2 (5,5%) of them has disease progression during the follow- up and they are being evaluated for a new SBRT. All of them have not grade >2 toxicity related to SBRT. 9 (25%) patients were included in a state of castration resistance without the need to start second generation hormonal This trial presents a favorable pace of recruitment with good initial figures of biochemical control and local control without the appearance of remarkable SBRT related toxicity at this time. EP-1321 Salvage Radiotherapy in locoregional macroscopically relapsed Prostate cancer:retrospective analysis A. Bruni 1 , G. Ingrosso 2 , E. Mazzeo 1 , L.M. Lamin 1 , B. Lanfranchi 1 , M. Andolina 1 , P. Morelli 2 , I. Turturici 2 , G. Guidi 3 , R. Santoni 2 1 AOU Policlinico of Modena, Radiation Oncology Unit, Modena, Italy 2 Tor Vergata University General Hospital, Radiation Oncology Unit, Rome, Italy 3 AOU Policlinico of Modena, Medical Physics Department, Modena, Italy this kind of approach. Material and Methods treatment. Conclusion

respectively

(Fig

Ia

and

b)

Conclusion A combination of radical and “adjuvant” radiotherapy in prostate cancer patients with synchronous oligometastatic bony disease at diagnosis and surgically managed show promising results in terms of both biochemical control and distant progression-free survival. The only severe event was probably caused by a previously used hypofractionated protocol for prostatic bed irradiation that was abandoned in 2013. EP-1320 Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer: Trial in progress. A. Conde Moreno (Spain), J. Lopez Torrecilla, J. Pastor Peidro, A. Hervás Morón, F. López-Campos, A. Mendez Villamón, M.M. Puertas Valiño, A. Sola Galarza, M. Rico Oses, P. Samper Ots, L.A. Pérez-Romasanta, C. Ibañez Villaoslada, J. Valero Albarrán, N. Ortiz Rodil, F. García Piñon, C. Ferrer Albiach 1 Consorcio Hosptialario Provincial de Castellon, RADIATION ONCOLOGY, Castellon, Spain 2 Eresa Hospital General De Valencia, RADIATION ONCOLOGY, VALENCIA, Spain 3 Hospital Ramón y Cajal, RADIATION ONCOLOGY, MADRID, Spain 4 Hospital Universitario Miguel Servet, RADIATION ONCOLOGY, ZARAGOZA, Spain 5 Complejo Hospitalario De Navarra, RADIATION ONCOLOGY, PAMPLONA, Spain 6 Hospital Rey Juan Carlos, RADIATION ONCOLOGY, MOSTOLES, Spain 7 Hospital Clínico De Salamanca, RADIATION ONCOLOGY, SALAMANCA, Spain 8 Hospital Central De La Defensa Gómez Ulla, RADIATION ONCOLOGY, MADRID, Spain 9 Hospital Universitario Sanchinarro Grupo HM,